The importance of appropriate antimicrobial dosing: Pharmacokinetic and pharmacodynamic considerations

被引:14
|
作者
Preston, SL [1 ]
机构
[1] Albany Med Coll, Clin Pharmacol Studies Unit, Albany, NY 12208 USA
关键词
D O I
10.1345/aph.1E218
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The increasing antimicrobial resistance of common respiratory pathogens has led to a reevaluation of the selection of antimicrobial dosing regimens in terms of their pharmacokinetic (PK) and pharmacodynamic (PD) properties. Pharmacokinetics, when considered as part of a specific dosing regimen, can help determine the time course of drug concentrations in the serum, tissues, body fluids, and at the site of infection. Pharmacodynamics provides surrogate markers for clinical and bacteriologic efficacy based on the relationships between the serum and tissue concentrations of selected antimicrobial agents relative to the mean inhibitory concentrations of causative bacteria over time. Ultimately, the interrelationships between PK and PD parameters measured for standard dosing regimens determine the time course of the drug's concentration at the site of infection and the impact of the agent's bacteriologic and clinical efficacy. In this review, the distinctive patterns of antimicrobial activity based on PK/PD parameters are discussed. Various antibiotics and bacterial pathogens are used as models to demonstrate the utility of PK/PD parameters in predicting the in vivo efficacy of antimicrobial therapy. The use of computer modeling with Monte Carlo population simulations can further enhance the predictability of antimicrobial efficacy when using PK/PD parameters. This article also provides a reevaluation of bacterial susceptibility breakpoints defined by the National Committee for Clinical Laboratory Standards contrasted with the use of PK/PD parameters.
引用
收藏
页码:S14 / S18
页数:5
相关论文
共 50 条
  • [31] Pharmacokinetic and Pharmacodynamic Basis for Effective Argatroban Dosing in Pediatrics
    Madabushi, Rajanikanth
    Cox, Donna S.
    Hossain, Mohammad
    Boyle, Duane A.
    Patel, Bela R.
    Young, Guy
    Choi, Young-Moon
    Gobburu, Jogarao V. S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (01): : 19 - 28
  • [32] Pharmacokinetic and pharmacodynamic considerations of cephalosporin use in children
    Tauzin, Manon
    Ouldali, Naim
    Bechet, Stephane
    Caeymaex, Laurence
    Cohen, Robert
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (11) : 869 - 880
  • [33] ANESTHESIA FOR THE AGED - SOME PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS
    MILLER, R
    MOUNT SINAI JOURNAL OF MEDICINE, 1987, 54 (04): : 305 - 307
  • [34] Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization
    White, Nicholas J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (12) : 5792 - 5807
  • [35] Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins
    Iftekhar Mahmood
    Martin D. Green
    Clinical Pharmacokinetics, 2005, 44 : 331 - 347
  • [36] Pharmacokinetic/pharmacodynamic considerations for epilepsy - depression comorbidities
    Banach, Monika
    Poplawska, Monika
    Blaszczyk, Barbara
    Borowicz, Kinga K.
    Czuczwar, Stanislaw J.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (09) : 1067 - 1080
  • [37] Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins
    Mahmood, I
    Green, MD
    CLINICAL PHARMACOKINETICS, 2005, 44 (04) : 331 - 347
  • [38] Use of opioids in the elderly - Pharmacokinetic and pharmacodynamic considerations
    Freye, E
    Levy, JV
    ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE, 2004, 39 (09): : 527 - 537
  • [39] Pharmacokinetic and Pharmacodynamic Considerations of Antibiotic Use in Neonates
    Regazzi, Mario
    Berardi, Alberto
    Picone, Simonetta
    Tzialla, Chryssoula
    ANTIBIOTICS-BASEL, 2023, 12 (12):
  • [40] Warfarin withdrawal - Pharmacokinetic-pharmacodynamic considerations
    Palareti, G
    Legnani, C
    CLINICAL PHARMACOKINETICS, 1996, 30 (04) : 300 - 313